Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.
2.
3.

Extended spectrum beta lactamase-producing Klebsiella pneumoniae infections: a review of the literature.

Gupta A, Ampofo K, Rubenstein D, Saiman L.

J Perinatol. 2003 Sep;23(6):439-43. Review.

4.

Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy.

Lee J, Pai H, Kim YK, Kim NH, Eun BW, Kang HJ, Park KH, Choi EH, Shin HY, Kim EC, Lee HJ, Ahn HS.

J Antimicrob Chemother. 2007 Sep;60(3):629-37. Epub 2007 Jun 27.

PMID:
17599919
5.

Emergence of carbapenem resistance due to porin loss in an extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae strain during meropenem therapy.

Webster DP, Gaulton T, Woodford N, Pike R, Turton J, Perry C, Bowler IC.

Int J Antimicrob Agents. 2010 Dec;36(6):575-6. doi: 10.1016/j.ijantimicag.2010.08.003. Epub 2010 Sep 24. No abstract available.

PMID:
20869852
6.

Septic arthritis due to extended spectrum beta lactamase producing Klebsiella pneumoniae.

Schelenz S, Bramham K, Goldsmith D.

Joint Bone Spine. 2007 May;74(3):275-8. Epub 2007 Mar 15. Review.

PMID:
17433752
8.

[Nosocomial meningitis with dual agents and treatment with intraventricular gentamicin].

Oztoprak N, Celebi G, Baruönü F, Kalayci M.

Mikrobiyol Bul. 2008 Jul;42(3):497-501. Turkish.

PMID:
18822895
9.

Spinal infection caused by ESBL-producing Klebsiella pneumoniae treated with temocillin.

Barton E, Flanagan P, Hill S.

J Infect. 2008 Oct;57(4):347-9. doi: 10.1016/j.jinf.2008.08.001. Epub 2008 Sep 19.

PMID:
18804871
10.

Nosocomial liver abscess caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae.

Lin JC, Siu LK, Fung CP, Yeh KM, Chang FY.

J Clin Microbiol. 2007 Jan;45(1):266-9. Epub 2006 Nov 8.

11.
12.
13.

An outbreak of SHV-5 producing Klebsiella pneumoniae in a neonatal intensive care unit; meropenem failed to avoid fecal colonization.

Gundes S, Arisoy AE, Kolayli F, Karaali E, Turker G, Sanic A, Arisoy ES, Vahaboglu H.

New Microbiol. 2005 Jul;28(3):231-6.

PMID:
16240695
14.

[Evaluation of the in vitro activity of meropenem against strains of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolated in the city of Fortaleza, Ceará].

Menezes EA, do Nascimento KM, Soares KP, Amorim LN, Lima Neto JG, Cunha FA.

Rev Soc Bras Med Trop. 2007 May-Jun;40(3):349-50. Portuguese.

15.

[Activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae].

de Cueto M, Hernández JR, López-Cerero L, Morillo C, Pascual A.

Enferm Infecc Microbiol Clin. 2006 Dec;24(10):613-6. Spanish.

PMID:
17194386
16.

Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.

Lee NY, Huang WH, Tsui KC, Hsueh PR, Ko WC.

Diagn Microbiol Infect Dis. 2011 May;70(1):150-3. doi: 10.1016/j.diagmicrobio.2010.12.008. Epub 2011 Mar 12.

PMID:
21398070
17.

Prevalence and contributing factors of nonsusceptibility to imipenem or meropenem in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.

Park YJ, Yu JK, Park KG, Park YG, Lee S, Kim SY, Jeong SH.

Diagn Microbiol Infect Dis. 2011 Sep;71(1):87-9. doi: 10.1016/j.diagmicrobio.2010.12.012. Epub 2011 Mar 11.

PMID:
21397426
19.
20.

Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain.

Hernández JR, Velasco C, Romero L, Martínez-Martínez L, Pascual A.

Int J Antimicrob Agents. 2006 Nov;28(5):457-9. Epub 2006 Sep 27.

PMID:
17008066

Supplemental Content

Support Center